U.S. patent application number 16/470943 was filed with the patent office on 2019-10-31 for process.
The applicant listed for this patent is AVECHO BIOTECHNOLOGY LIMITED. Invention is credited to Paul David Gavin, Stephen Geytenbeek, Andrew Stirling.
Application Number | 20190330260 16/470943 |
Document ID | / |
Family ID | 62624385 |
Filed Date | 2019-10-31 |
United States Patent
Application |
20190330260 |
Kind Code |
A1 |
Geytenbeek; Stephen ; et
al. |
October 31, 2019 |
PROCESS
Abstract
An efficient and commercial phosphorylation process of a complex
alcohol, such as secondary and tertiary alcohols, with
P.sub.4O.sub.10 at high temperatures, and a product obtained by the
process.
Inventors: |
Geytenbeek; Stephen;
(Clayton, Victoria, AU) ; Stirling; Andrew;
(Clayton, Victoria, AU) ; Gavin; Paul David;
(Clayton, Victoria, AU) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AVECHO BIOTECHNOLOGY LIMITED |
Clayton, Victoria |
|
AU |
|
|
Family ID: |
62624385 |
Appl. No.: |
16/470943 |
Filed: |
December 13, 2017 |
PCT Filed: |
December 13, 2017 |
PCT NO: |
PCT/AU2017/051381 |
371 Date: |
June 18, 2019 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07F 9/095 20130101;
C07F 9/12 20130101; C07F 9/65522 20130101; C07F 9/11 20130101; C07J
51/00 20130101; C07J 9/00 20130101; C07F 9/09 20130101 |
International
Class: |
C07J 51/00 20060101
C07J051/00; C07F 9/09 20060101 C07F009/09 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 21, 2016 |
AU |
2016905298 |
Claims
1-20. (canceled)
21. A process for phosphorylating a complex alcohol, comprising the
steps of: (a) mixing the complex alcohol and P.sub.4O.sub.10 until
its exothermic reaction temperature is achieved; (b) allowing the
reaction mixture of step (a) to react until the exothermic reaction
is complete and, if the temperature of the reaction mixture at this
point is not at least 90.degree. C., heating the reaction mixture
to within a range of 90.degree. C. to 140.degree. C.; (c) cooling
the reaction mixture of step (b) to at least 80.degree. C.; and (d)
hydrolysing the reaction mixture of step (c), wherein hydrolysis is
conducted for 30 to 90 minutes.
22. The process of claim 21 wherein the complex alcohol is a linear
or branched alcohol comprising at least 6 carbon atoms, or a cyclic
complex alcohol.
23. The process of claim 21 wherein the cyclic complex alcohol is
carbocyclic, heterocyclic, monocyclic or polycyclic.
24. The process of claim 21 wherein the complex alcohol is a
chromanol.
25. The process of claim 24 wherein the chromanol is a tocopherol
or tocotrienol.
26. The process of claim 21 wherein step (d) involves the addition
of an aqueous solution.
27. The process of claim 21 wherein, in step (b) and/or (c), the
temperature of the reaction mixture is maintained for 30 to 180
minutes, 60 to 180 minutes, 60 to 120 minutes, or 60 minutes.
28. The process of claim 21 wherein the temperature of the reaction
mixture during the hydrolysis step (d) is at least 80.degree. C.,
within the range of at least 80.degree. C. to 150.degree. C.,
within the range of 85.degree. C. to 120.degree. C., within the
range of 90.degree. C. to 110.degree. C., within the range of
90.degree. C. to 100.degree. C., or within the range of 100.degree.
C. to 110.degree. C.
29. The process of claim 21 wherein hydrolysis is conducted for 60
to 90 minutes.
30. The process of claim 21 wherein the product of the hydrolysis
step (d) is a mixture of a phosphorylated mono-complex alcohol and
a phosphorylated di-complex alcohol.
31. The process of claim 21 wherein the molar ratio of the mixture
of the phosphorylated mono-complex alcohol and the phosphorylated
di-complex alcohol is within a range of 6:4 to 8:2, or is 2:1.
32. The process of claim 21 wherein the process further comprises
the step of reacting the reaction mixture of step (d) with an
amphoteric surfactant, wherein the amphoteric surfactant is a
tertiary amine of the formula N.sub.1R.sub.1R.sub.2R.sub.3, wherein
R.sub.1 is selected from the group consisting of C.sub.6-22 alkyl,
and R.sub.2 and R.sub.3 are independently selected from the group
consisting of H, (CH.sub.2).sub.nCOOX,
(CH.sub.2).sub.nCHOHCH.sub.2SO.sub.3X,
(CH.sub.2).sub.nCHOHCH.sub.2OPO.sub.3X, in which X is H or forms a
salt with a cation selected from the group consisting of sodium,
potassium, lithium, calcium, magnesium, ammonium, alkylammonium and
alkanolamine, and n is 1 or 2.
33. The process of claim 32 wherein the tertiary amine is selected
from the group consisting of 3-[2-carboxyethyl(dodecyl)amino]
propanoic acid, 3,3'-(dodecylimino)dipropionic acid monosodium
salt, lauryliminodipropionic acid, sodium lauryliminodipropionate
and N-lauryl iminodipropionate.
Description
TECHNICAL FIELD
[0001] The invention relates to a phosphorylation process of
complex alcohols, and products obtained by that process.
BACKGROUND
[0002] It is to be understood that, if any prior art publication is
referred to herein, such reference does not constitute an admission
that the publication forms a part of the common general knowledge
in the art, in Australia or any other country.
[0003] Phosphorylation processes and reagents are chosen to avoid
significant degradation of the compound being phosphorylated and to
produce desired yields.
[0004] In some phosphorylation processes, reagents such as
2:2:2-trichloroethyl dichlorophosphate, di-imidazolide
chlorophosphate and di-analide chlorophosphate are used under
gentle conditions to avoid degradation of the compound being
phosphorylated. However, such processes have been found to produce
limited yields, which would not be economical or suitable for
commercial purposes.
[0005] In other phosphorylation processes, the reagent phosphorous
oxychloride is used, but the reaction typically produces a variety
of by-products and hydrogen chloride. Such process may also not be
commercially viable given that the reagent phosphorous oxychloride
is difficult to handle.
[0006] The reagent P.sub.4O.sub.10, which is commonly known as
phosphorus pentoxide, but has other names such as phosphorus (V)
oxide, phosphoric anhydride and diphosphorus pentoxide, is a white
crystalline solid. This reagent has been used for phosphorylation
of ethanol and other short chain primary alcohols (i.e. less than 6
carbon atoms) and it has been found to be suitable for
phosphorylation of alcohols such as primary fatty alcohols,
secondary alcohols and aromatic alcohols. Australian Patent No.
200043870 describes a process, which involves forming an intimate
mixture of one or more of these alcohols and P.sub.4O.sub.10,
partly hydrated P.sub.4O.sub.10 or a mixture thereof, at a
temperature below 80.degree. C., and allowing the intimate mixture
to continue to react for a period of time at this temperature, i.e.
below 80.degree. C., until formation of the phosphorylated alcohol
is substantially formed. It is clear that the temperature must be
kept to a minimum and below 80.degree. C. to avoid degradation.
[0007] The phosphorylation of complex alcohols, such as secondary
and tertiary alcohols, with P.sub.4O.sub.10 at higher temperatures
was thought to lead to degradation and/or side reactions such as
dehydration and double bond formation. These problems teach away
from the use of P.sub.4O.sub.10 for the efficient and commercial
phosphorylation of complex alcohols at high temperatures.
[0008] The present inventors have found that complex alcohols can
be phosphorylated at a high temperature and that, at such
temperatures, desirable yields can be obtained with minimal
degradation of the complex alcohols.
SUMMARY
[0009] Accordingly, there is provided a process for phosphorylating
a complex alcohol, comprising the steps of: [0010] (a) mixing the
complex alcohol and P.sub.4O.sub.10 until its exothermic reaction
temperature is achieved; [0011] (b) allowing the reaction mixture
of step (a) to react until the exothermic reaction is complete;
[0012] (c) heating or cooling the reaction mixture of step (b) to
at least 80.degree. C.; and [0013] (d) hydrolysing the reaction
mixture of step (c).
[0014] There is also provided a product obtained by the
process.
DETAILED DESCRIPTION
[0015] The invention relates to a process for phosphorylating a
complex alcohol, comprising the steps of: [0016] (a) mixing the
complex alcohol and P.sub.4O.sub.10 until its exothermic reaction
temperature is achieved; [0017] (b) allowing the reaction mixture
of step (a) to react until the exothermic reaction is complete;
[0018] (c) heating or cooling the reaction mixture of step (b) to
at least 80.degree. C.; and [0019] (d) hydrolysing the reaction
mixture of step (c).
Complex Alcohol
[0020] The complex alcohol may be a linear or branched alcohol
comprising at least 6 carbon atoms (i.e. 6 or more carbon atoms).
In some embodiments, the complex alcohol comprises at least 7
carbon atoms. In other embodiments, the complex alcohol comprises
at least 8 carbon atoms. In particular embodiments, the complex
alcohol comprises at least 10 carbon atoms. The number of carbon
atoms mentioned herein refers to the number of carbon atoms that
make up the backbone of the linear or branched complex alcohol or
the ring system of the cyclic complex alcohol.
[0021] Examples of linear and branched complex alcohols include,
but are not limited to, hexanol, hexan-1-ol, heptanol, heptan-1-ol,
octanol, octan-1-ol, decanol, decan-1-ol, undecanol, dodecanol,
1-dodecanol, tridecanol, 1-tetradecanol, pentadecanol, cetyl
alcohol, stearyl alcohol, 1-methylhexan-1-ol, 2-methylhexan-1-ol,
3-methyl-heptan-1-ol, 4-methylhexan-1-ol, 1-methylhexan-2-ol,
2-methylhexan-2-ol, 3-methyl-hexan-2-ol, 4-methylhexan-2-ol,
1-methylhexan-3-ol, 2-methylhexan-3-ol, 3-methyl-hexan-3-ol,
4-methylhexan-3-ol, 1-methylhexan-4-ol, 2-methylhexan-4-ol,
3-methyl-hexan-4-ol, 4-methylhexan-4-ol, 1-methylhexan-5-ol,
2-methylhexan-5-ol, 3-methyl-hexan-5-ol, 4-methylhexan-5-ol,
1-methylhexan-6-ol, 2-methylhexan-6-ol, 3-methyl-hexan-6-ol,
4-methylhexan-6-ol, 1-ethylhexan-1-ol, 2-ethylhexan-1-ol,
3-ethyl-hexan-1-ol, 4-methylhexan-1-ol, 1-ethylhexan-2-ol,
2-ethylhexan-2-ol, 3-ethyl-hexan-2-ol, 4-ethylhexan-2-ol,
1-ethylhexan-3-ol, 2-ethylhexan-3-ol, 3-ethyl-hexan-3-ol,
4-ethylhexan-3-ol, 1-ethylhexan-4-ol, 2-ethylhexan-4-ol,
3-ethyl-hexan-4-ol, 4-ethylhexan-4-ol, 1-ethylhexan-5-ol,
2-ethylhexan-5-ol, 3-ethyl-hexan-5-ol, 4-ethylhexan-5-ol,
1-ethylhexan-6-ol, 2-ethylhexan-6-ol, 3-ethyl-hexan-6-ol,
4-ethylhexan-6-ol, 1-methylheptan-1-ol, 2-methylheptan-1-ol,
3-methyl-heptan-1-ol, 4-methylheptan-1-ol, 1-methylheptan-2-ol,
2-methylheptan-2-ol, 3-methyl-heptan-2-ol, 4-methylheptan-2-ol,
1-methylheptan-3-ol, 2-methylheptan-3-ol, 3-methyl-heptan-3-ol,
4-methylheptan-3-ol, 1-methylheptan-4-ol, 2-methylheptan-4-ol,
3-methyl-heptan-4-ol, 4-methylheptan-4-ol, 1-methylheptan-5-ol,
2-methylheptan-5-ol, 3-methyl-heptan-5-ol, 4-methylheptan-5-ol,
1-methylheptan-6-ol, 2-methylheptan-6-ol, 3-methyl-heptan-6-ol,
4-methylheptan-6-ol, 1-methylheptan-7-ol, 2-methylheptan-7-ol,
3-methyl-heptan-7-ol, 4-methylheptan-7-ol, 1-ethylheptan-1-ol,
2-ethylheptan-1-ol, 3-ethyl-heptan-1-ol, 4-methylheptan-1-ol,
1-ethylheptan-2-ol, 2-ethylheptan-2-ol, 3-ethyl-heptan-2-ol,
4-ethylheptan-2-ol, 1-ethylheptan-3-ol, 2-ethylheptan-3-ol,
3-ethyl-heptan-3-ol, 4-ethylheptan-3-ol, 1-ethylheptan-4-ol,
2-ethylheptan-4-ol, 3-ethyl-heptan-4-ol, 4-ethylheptan-4-ol,
1-ethylheptan-5-ol, 2-ethylheptan-5-ol, 3-ethyl-heptan-5-ol,
4-ethylheptan-5-ol, 1-ethylheptan-6-ol, 2-ethylheptan-6-ol,
3-ethyl-heptan-6-ol, 4-ethylheptan-6-ol, 1-ethylheptan-7-ol,
2-ethylheptan-7-ol, 3-ethyl-heptan-7-ol, 4-ethylheptan-7-ol,
1-methyloctan-1-ol, 2-methyloctan-1-ol, 3-methyl-octan-1-ol,
4-methyloctan-1-ol, 1-methyloctan-2-ol, 2-methyloctan-2-ol,
3-methyl-octan-2-ol, 4-methyloctan-2-ol, 1-methyloctan-3-ol,
2-methyloctan-3-ol, 3-methyl-octan-3-ol, 4-methyloctan-3-ol,
1-methyloctan-4-ol, 2-methyloctan-4-ol, 3-methyl-octan-4-ol,
4-methyloctan-4-ol, 1-methyloctan-5-ol, 2-methyloctan-5-ol,
3-methyl-octan-5-ol, 4-methyloctan-5-ol, 1-methyloctan-6-ol,
2-methyloctan-6-ol, 3-methyl-octan-6-ol, 4-methyloctan-6-ol,
1-methyloctan-7-ol, 2-methyloctan-7-ol, 3-methyl-octan-7-ol,
4-methyloctan-7-ol, 1-methyloctan-8-ol, 2-methyloctan-8-ol,
3-methyl-octan-8-ol, 4-methyloctan-8-ol, 1-ethyloctan-1-ol,
2-ethyloctan-1-ol, 3-ethyl-octan-1-ol, 4-methyloctan-1-ol,
1-ethyloctan-2-ol, 2-ethyloctan-2-ol, 3-ethyl-octan-2-ol,
4-ethyloctan-2-ol, 1-ethyloctan-3-ol, 2-ethyloctan-3-ol,
3-ethyl-octan-3-ol, 4-ethyloctan-3-ol, 1-ethyloctan-4-ol,
2-ethyloctan-4-ol, 3-ethyl-octan-4-ol, 4-ethyloctan-4-ol,
1-ethyloctan-5-ol, 2-ethyloctan-5-ol, 3-ethyl-octan-5-ol,
4-ethyloctan-5-ol, 1-ethyloctan-6-ol, 2-ethyloctan-6-ol,
3-ethyl-octan-6-ol, 4-ethyloctan-6-ol, 1-ethyloctan-7-ol,
2-ethyloctan-7-ol, 3-ethyl-octan-7-ol, 4-ethyloctan-7-ol,
1-ethyloctan-8-ol, 2-ethyloctan-8-ol, 3-ethyl-octan-8-ol,
4-ethyloctan-8-ol, 1-methylnonan-1-ol, 2-methylnonan-1-ol,
3-methyl-nonan-1-ol, 4-methylnonan-1-ol, 1-methylnonan-2-ol,
2-methylnonan-2-ol, 3-methyl-nonan-2-ol, 4-methylnonan-2-ol,
1-methylnonan-3-ol, 2-methylnonan-3-ol, 3-methyl-nonan-3-ol,
4-methylnonan-3-ol, 1-methylnonan-4-ol, 2-methylnonan-4-ol,
3-methyl-nonan-4-ol, 4-methylnonan-4-ol, 1-methylnonan-5-ol,
2-methylnonan-5-ol, 3-methyl-nonan-5-ol, 4-methylnonan-5-ol,
1-methylnonan-6-ol, 2-methylnonan-6-ol, 3-methyl-nonan-6-ol,
4-methylnonan-6-ol, 1-methylnonan-7-ol, 2-methylnonan-7-ol,
3-methyl-nonan-7-ol, 4-methylnonan-7-ol, 1-methylnonan-8-ol,
2-methylnonan-8-ol, 3-methyl-nonan-8-ol, 4-methylnonan-8-ol,
1-methylnonan-9-ol, 2-methylnonan-9-ol, 3-methyl-nonan-9-ol,
4-methylnonan-9-ol, 1-ethylnonan-1-01, 2-ethylnonan-1-ol,
3-ethyl-nonan-1-ol, 4-methylnonan-1-ol, 1-ethylnonan-2-ol,
2-ethylnonan-2-ol, 3-ethyl-nonan-2-ol, 4-ethylnonan-2-ol,
1-ethylnonan-3-ol, 2-ethylnonan-3-ol, 3-ethyl-nonan-3-ol,
4-ethylnonan-3-ol, 1-ethylnonan-4-ol, 2-ethylnonan-4-ol,
3-ethyl-nonan-4-ol, 4-ethylnonan-4-ol, 1-ethylnonan-5-ol,
2-ethylnonan-5-ol, 3-ethyl-nonan-5-ol, 4-ethylnonan-5-ol,
1-ethylnonan-6-ol, 2-ethylnonan-6-ol, 3-ethyl-nonan-6-ol,
4-ethylnonan-6-ol, 1-ethylnonan-7-ol, 2-ethylnonan-7-ol,
3-ethyl-nonan-7-ol, 4-ethylnonan-7-ol, 1-ethylnonan-8-ol,
2-ethylnonan-8-ol, 3-ethyl-nonan-8-ol, 4-ethylnonan-8-ol,
1-ethylnonan-9-ol, 2-ethylnonan-9-ol, 3-ethyl-nonan-9-ol, and
4-ethylnonan-9-ol.
[0022] The complex alcohol may be a cyclic complex alcohol and may
be carbocyclic or heterocyclic. Further, the carbocyclic or
heterocyclic complex alcohol may be aromatic or non-aromatic. In
some embodiments, the heterocyclic complex alcohol comprises one or
more heteroatoms. In one embodiment, the heterocyclic complex
alcohol comprises one heteroatom. In another embodiment, the
heterocyclic complex alcohol comprises two heteroatoms. The
heteroatom may be selected from the group consisting of N, O, S and
P.
[0023] The cyclic complex alcohol may also be monocyclic or
polycyclic. The polycyclic complex alcohol may comprise 2 or more
rings. In some embodiments, the polycyclic complex alcohol
comprises 2 or more rings, wherein at least 2 rings are fused.
[0024] In particular embodiments, the complex alcohol is a sterol.
The sterol may be a phytosterol. In one specific embodiment, the
sterol is cholesterol.
[0025] In other particular embodiments, the complex alcohol is a
chromanol. In some embodiments, the chromanol is a tocopherol or
tocotrienol.
[0026] In some embodiments, the tocopherol is natural, synthetic,
or a combination thereof. Natural tocopherol typically comprises
about 96% .alpha.-tocopherol and a small amount of
.gamma.-tocopherol. Synthetic tocopherol, on the other hand,
typically comprises about 99-98% .alpha.-tocopherol. Furthermore,
synthetic tocopherol comprises a mixture of the 8 possible
stereoisomers, where only 1 occurs naturally.
[0027] In other embodiments, the tocopherol is .alpha.-tocopherol,
.beta.-tocopherol, .gamma.-tocopherol, tocopherol, or a combination
thereof. In particular embodiments, the tocopherol comprises
a-tocopherol. In one embodiment, the tocopherol comprises equal to
or greater than about 90% .alpha.-tocopherol. In another
embodiment, the tocopherol is a-tocopherol (i.e. 100%
.alpha.-tocopherol).
[0028] The complex alcohol may also be a pharmaceutical compound,
an anaesthetic, or an antioxidant.
[0029] In some embodiments, the pharmaceutical compound is an
oncology drug such as a taxane, a nucleoside or a kinase inhibitor,
a steroid, an opioid analgesic, a respiratory drug, a central
nervous system (CNS) drug, a hypercholesterolemia drug, an
antihypertensive drug, an immunosuppressive drug, an antibiotic, a
luteinising hormone releasing hormone (LHRH) agonist, a LHRH
antagonist, an antiviral drug, an antiretroviral drug, an estrogen
receptor modulator, a somatostatin mimic, an anti-inflammatory
drug, a vitamin D.sub.2 analogue, a synthetic thyroxine, an
antihistamine, an antifungal agent, a nonsteroidal
anti-inflammatory drug (NSAID) or an anesthetic.
[0030] Suitable oncology drugs include taxanes such as paclitaxel,
cabazitaxel and docetaxel, camptothecin and its analogues such as
irinotecan and topotecan, other antimicrotubule agents such as
vinflunine, nucleosides such as gemcitabine, cladribine,
fludarabine capecitabine, decitabine, azacitidine, clofarabine and
nelarabine, kinase inhibitors such as sprycel, temisirolimus,
dasatinib, AZD6244, AZD1152, PI-103, R-roscovitine, olomoucine and
purvalanol A, and epothilone B analogues such as ixabepilone,
anthrocyclines such as amrubicin, doxorubicin, epirubicin and
valrubicin, super oxide inducers such as trabectecin, proteosome
inhibitors such as bortezomib and other topoisomerase inhibitors,
intercalating agents and alkylating agents.
[0031] Suitable steroids include anabolic steroids such as
testosterone, dihydrotestosterone, estradiol and ethynylestradiol,
and corticosteroids such as cortisone, prednisilone, budesonide,
triamcinolone, fluticasone, mometasone, amcinonide, flucinolone,
fluocinanide, desonide, halcinonide, prednicarbate, fluocortolone,
dexamethasone, betamethasone and fluprednidine.
[0032] Suitable opioid analgesics include morphine, oxymorphone,
naloxone, codeine, oxycodone, methylnaltrexone, hydromorphone,
buprenorphine and etorphine.
[0033] Suitable respiratory drugs include bronchodilators, inhaled
steroids, and decongestants and more particularly salbutamol,
ipratropium bromide, montelukast and formoterol. Suitable CNS drugs
include antipsychotic such as quetiapine and antidepressants such
as venlafaxine.
[0034] Suitable drugs to control hypercholesterolemia include
ezetimibe and statins such as simvastatin, lovastatin,
atorvastatin, fluvastatin, pitavastatin, pravastatin and
rosuvastatin.
[0035] Suitable antihypertensive drugs include losartan,
olmesartan, medoxomil, metrolol, travoprost and bosentan.
[0036] Suitable immunosuppressive drugs include glucocorticoids,
cytostatics, antibody fragments, anti-immunophilins, interferons,
TNF binding proteins and more particularly, cacineurin inhibitors
such as tacrolimus, mycophenolic acid and its derivatives such as
mycophenolate mofetil, and cyclosporine.
[0037] Suitable antibacterial agents include antibiotics such as
amoxicillin, meropenem and clavulanic acid.
[0038] Suitable LHRH agonists include goserelin acetate, deslorelin
and leuprorelin.
[0039] Suitable LHRH antagonists include cetrorelix, ganirelix,
abarelix and degarelix.
[0040] Suitable antiviral agents include nucleoside analogs such as
lamivudine, zidovudine, abacavir and entecavir and suitable
antiretro viral drugs include protease inhibitors such as
atazanavir, lapinavir and ritonavir. Suitable selective estrogen
receptor modulators include raloxifene and fulvestrant.
[0041] Suitable somastatin mimics include octreotide.
[0042] Suitable anti-inflammatory drugs include mesalazine and
suitable NSAIDs include acetaminophen (paracetamol).
[0043] Suitable vitamin D.sub.2 analogues include paricalcitol.
[0044] Suitable synthetic thyroxines include levothyroxine.
[0045] Suitable anti-histamines include fexofenadine.
[0046] Suitable antifungal agents include azoles such as
viriconazole.
[0047] Suitable antioxidants include ascorbic acid, hydroxy
carotenoids such as retinol, and calciferol.
[0048] Suitable anesthetics include propofol.
[0049] The complex alcohol may also be a solvent, such as, for
example, tetraglycol and lauryl alcohol.
[0050] In some embodiments, the complex alcohol is sparingly
soluble or insoluble in aqueous solution. For example, the complex
alcohol may be farnesol.
[0051] In some embodiments, the complex alcohol may be a mixture of
two or more complex alcohols.
[0052] In the above embodiments, the linear, branched or cyclic
complex alcohol is monohydroxy or polyhydroxy. In some embodiments,
the polyhydroxy complex alcohol comprises 2 hydroxy groups. In
other embodiments, the polyhydroxy complex alcohol comprises more
than 2 hydroxy groups. For example, the polyhydroxy complex alcohol
may comprise 3, 4 or 5 hydroxy groups. In particular embodiments,
the complex alcohol is a monohydroxy complex alcohol.
[0053] In the above embodiments, the linear, branched or cyclic
complex alcohol may be unsubstituted or substituted with one or
more substituent groups. Unless otherwise defined, the term
"substituted" or "substituent" as used herein refers to a group
which may or may not be further substituted with one or more groups
selected from C.sub.1-6alkyl, C.sub.1-6alkynyl, aryl, aldehyde,
halogen, haloC.sub.1-6alkyl, haloC.sub.1-6alkenyl,
haloC.sub.1-6alkynyl, haloaryl, hydroxy, C.sub.1-6alkylhydroxy,
C.sub.1-6alkoxy, --OC.sub.1-6alkylhydroxy,
--OC.sub.1-6alkylC.sub.1-6alkoxy, C.sub.1-6alkenyloxy, aryloxy,
benzyloxy, haloC.sub.1-6alkoxy, haloC.sub.1-6alkenyloxy,
haloaryloxy, nitro, nitroC.sub.1-6alkyl, nitroC.sub.1-6alkenyl,
nitroC.sub.1-6alkynyl, nitroaryl, nitroheterocyclyl, amino,
C.sub.1-6alkylamino, C.sub.1-6dialkylamino, C.sub.1-6alkenylamino,
C.sub.1-6alkynylamino, arylamino, diarylamino, benzylamino,
dibenzylamino, acyl, C.sub.1-6alkenylacyl, C.sub.1-6alkynylacyl,
arylacyl, acylamino, diacylamino, acyloxy, alkylsulphonyloxy,
arylsulphenyloxy, heterocyclyl, heterocycloxy, heterocyclamino,
haloheterocyclyl, alkylsulphenyl, arylsulphenyl, carboalkoxy,
carboaryloxy, mercapto, benzylthio, acylthio, and
phosphorus-containing groups.
Phosphorylation Reagent
[0054] The complex alcohol is mixed with P.sub.4O.sub.10. In some
embodiments, the P.sub.4O.sub.10 may be partly hydrated (or a
polyphosphoric acid).
[0055] The molar ratio of hydroxyl group (of the complex alcohol)
to phosphorus may be within a range of about 3:1 to about 1:3. In
some embodiments, the molar ratio is within the range of about 2:1
to about 1:2. In one embodiment, the molar ratio is about 2:1.
[0056] In another embodiment, the molar ratio is about 1:1, or
substantially equimolar. In this particular embodiment, the molar
ratio of hydroxyl group (of the complex alcohol) to P.sub.4O.sub.10
would be about 1:0.25.
Process
[0057] The process is for phosphorylating a complex alcohol,
comprising the steps of: [0058] (a) mixing the complex alcohol and
P.sub.4O.sub.10 until its exothermic reaction temperature is
achieved; [0059] (b) allowing the reaction mixture of step (a) to
react until the exothermic reaction is complete; [0060] (c) heating
or cooling the reaction mixture of step (b) to at least 80.degree.
C.; and [0061] (d) hydrolysing the reaction mixture of step
(c).
Step (a)
[0062] This step involves mixing the complex alcohol and
P.sub.4O.sub.10 until its exothermic reaction temperature is
achieved.
[0063] The meaning of "exothermic reaction" is well known in the
relevant art. It describes a chemical reaction that releases energy
by light or, as in the present invention, heat. The term
"exothermic reaction temperature" is used herein to refer to the
temperature at which the chemical reaction between the complex
alcohol and P.sub.4O.sub.10 commences to release heat. The complex
alcohol and P.sub.4O.sub.10 are mixed until its exothermic reaction
temperature is achieved, and may be mixed to form an intimate
mixture. Mixing may be achieved by any available means, including
stirring (manual or mechanical). In some embodiments, mixing may
also involve the use a high-shear mixer.
[0064] In some embodiments, this step may also involve heating the
complex alcohol and P.sub.4O.sub.10 to advance the chemical
reaction between the complex alcohol and P.sub.4O.sub.10to its
exothermic reaction temperature. For example, the complex alcohol
and P.sub.4O.sub.10 may be heated so that its exothermic reaction
temperature is achieved in a shorter period of time. For example,
the complex alcohol and P.sub.4O.sub.10 may be heated to advance
the chemical reaction between the complex alcohol and
P.sub.4O.sub.10to its exothermic reaction temperature in about 15
to 30 minutes.
[0065] In other embodiments, no heating is applied so that the
chemical reaction between the complex alcohol and P.sub.4O.sub.10
achieves its exothermic reaction temperature over the time needed
to reach this temperature.
Step (b)
[0066] This step involves allowing the reaction mixture of step (a)
to react until the exothermic reaction is complete. In some
embodiments, as the reaction progresses, heat is generated by the
exothermic reaction process and the temperature of the reaction
rises without external heating.
[0067] The exothermic reaction is complete when the temperature of
the chemical reaction between the complex alcohol and
P.sub.4O.sub.10 begins to fall.
[0068] In some embodiments, this step does not involve mixing. In
alternate embodiments, this step involves mixing. As mentioned
above, mixing may be achieved by any available means, including
stirring (manual or mechanical), and may also involve the use of a
high-shear mixer.
Step (c)
[0069] This step involves heating or cooling the reaction mixture
of step (b) to at least 80.degree. C.
[0070] In this step, the temperature is at least 80.degree. C. The
term "at least 80.degree. C." is used herein to refer to a
temperature equal to or greater than 80.degree. C. In some
embodiments, the temperature is within the range of at least
80.degree. C. to about 160.degree. C. In other embodiments, the
temperature is within the range of about 90.degree. C. to
140.degree. C. In one embodiment, the temperature is about
90.degree. C. In another embodiment, the temperature is about
100.degree. C. In yet another embodiment, the temperature is about
110.degree. C.
[0071] The reaction mixture of step (b) will be cooled to the
relevant temperature if the temperature of the reaction mixture of
step (b) is higher than this temperature after the exothermic
reaction between the complex alcohol and P.sub.4O.sub.10 is
complete. In the alternative, the reaction mixture of step (b) will
be heated to the relevant temperature if the temperature of the
reaction mixture of step (b) is lower than this temperature after
the exothermic reaction between the complex alcohol and
P.sub.4O.sub.10 is complete.
[0072] In some embodiments, the heating or cooling of the reaction
mixture of step (b) may be allowed to proceed gradually over time.
In other embodiments, the time may be limited to a specific period
of time. For example, the period of time may be limited to about 30
to about 90 minutes, after which external means is used to further
heat or to further cool the reaction mixture of step (b).
[0073] Once at the heated or cooled temperature, the reaction
mixture of step (b) may be maintained at this temperature for about
30 to about 180 minutes. In some embodiments, the reaction mixture
of step (b) is maintained at this temperature for about 60 to about
180 minutes. In one embodiment, the reaction mixture of step (b) is
maintained at this temperature for about 60 to about 120 minutes.
In another embodiment, the reaction mixture of step (b) is
maintained at this temperature for about 60 minutes.
Step (d)
[0074] This step involves hydrolysing the reaction mixture of step
(c).
[0075] Hydrolysis involves the addition of an aqueous solution. The
aqueous solution may be water (e.g. deionised water). In some
embodiments, an excess amount of water is added during the step of
hydrolysis. During hydrolysis, the reaction mixture of step (c) may
be maintained at the hydrolysis temperature of at least 80.degree.
C. The term "at least 80.degree. C." has the meaning mentioned
above. In some embodiments, the hydrolysis temperature is within
the range of at least 80.degree. C. to about 150.degree. C. In some
embodiments, the hydrolysis temperature is within the range of
about 85.degree. C. to 120.degree. C. In one embodiment, the
hydrolysis temperature is within the range of about 90.degree. C.
to 110.degree. C. In another embodiment, the hydrolysis temperature
is within the range of about 90.degree. C. to 100.degree. C. In yet
another embodiment, the hydrolysis temperature is within the range
of about 100.degree. C. to 110.degree. C.
[0076] Hydrolysis may be conducted for about 30 to about 180
minutes. In some embodiments, hydrolysis is conducted for about 30
to about 120 minutes. In one embodiment, hydrolysis is conducted
for about 60 to about 120 minutes. In another embodiment,
hydrolysis is conducted for about 90 to about 120 minutes. In one
embodiment, hydrolysis is conducted for about 60 to about 90
minutes.
Optional Solvent
[0077] The process may be conducted in the absence of an additional
solvent. The term "additional solvent" is used herein to refer to a
solvent other than the aqueous solution, such as water, used during
the step of hydrolysis. In some embodiments, the reaction is
conducted without an additional solvent such that the complex
alcohol and P.sub.4O.sub.10 are mixed in neat form.
Product
[0078] The invention also relates to a product obtained by the
process. The product obtained by the process may be a
phosphorylated mono-complex alcohol, a phosphorylated di-complex
alcohol, or a mixture thereof. In particular embodiments, the
product is a mixture of a phosphorylated mono-complex alcohol and a
phosphorylated di-complex alcohol. In these embodiments, the molar
ratio of the mixture of the phosphorylated mono-complex alcohol and
the phosphorylated di-complex alcohol may be at least about 2:1,
about 2:1, about 6:4 or about 8:2, or within a range of about 4:1
to about 1:4 or about 6:4 to about 8:2.
[0079] In some embodiments, the product obtained by the process may
be a cross-coupled phosphate diester.
[0080] It should be appreciated that the product obtained by the
process may also comprise residual amounts of unreacted complex
alcohol and/or related substances. In such embodiments, the process
may further involve purification steps.
Further Process Steps to Obtain Further Products
[0081] The product obtained by the process may also be further
reacted with an amphoteric surfactant.
[0082] In these embodiments, the complex alcohol is a tocopherol,
and the phosphorylated complex alcohol is a tocopheryl phosphate.
The tocopheryl phosphate may be a mono-tocopheryl phosphate, a
di-tocopheryl phosphate, or a mixture thereof.
[0083] In one embodiment, the amphoteric surfactant is a tertiary
amine of the formula NR.sub.1R.sub.2R.sub.3, wherein R.sub.1 is
selected from the group consisting of C.sub.6-22 alkyl, and R.sub.2
and R.sub.3 are independently selected from the group consisting of
H, (CH.sub.2).sub.nCOOX, (CH.sub.2).sub.nCHOHCH.sub.2SO.sub.3X,
(CH.sub.2).sub.nCHOHCH.sub.2OPO.sub.3X, in which X is H or forms a
salt with a cation selected from the group consisting of sodium,
potassium, lithium, calcium, magnesium, ammonium, alkylammonium and
alkanolamine, and n is 1 or 2.
[0084] The term "C.sub.6-22 alkyl" refers to a straight or branched
chain or cyclic hydrocarbon group having from 6 to 22 carbon atoms.
Examples include, but are not limited to, hexyl, cyclohexyl, decyl,
dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl
and octadecyl.
[0085] In some embodiments, R.sub.1 is a C.sub.12 alkyl (dodecyl),
and R.sub.2 and R.sub.3 are independently selected from
CH.sub.2CH.sub.2COOH and CH.sub.2CH.sub.2COONa.
[0086] In particular embodiments, the tertiary amine is
3-[2-carboxyethyl(dodecyl)amino] propanoic acid. In other
embodiments, the tertiary amine is 3,3'-dodecylimino)dipropionic
acid monosodium salt (or lauryliminodipropionic acid, sodium
lauryliminodipropionate or N-lauryl iminodipropionate).
[0087] The product obtained by this further process may be
lauryliminodipropionic acid tocopheryl phosphates or a salt
thereof. In some embodiments, the salt is a sodium salt.
EXAMPLES
[0088] Various embodiments/aspects of the present invention will
now be described with reference to the following non-limiting
examples.
Example 1
[0089] Synthetic .alpha.-tocopherol and P.sub.4O.sub.10 were mixed
(mass ratio 0.170), and with heating, the exothermic reaction
temperature was reached within about 15 minutes. Heating was
continued until the reaction mixture a temperature of about
120.degree. C. was achieved and then stopped. The temperature of
the reaction mixture continued to rise for a brief period of time.
When the exothermic reaction was complete, the reaction mixture was
allowed to cool without any external control for about 60 minutes.
The reaction was then further cooled to a temperature of about
90.degree. C. before hydrolysis was conducted with deionised water
for about 60 minutes.
[0090] The process produced about 58.52% w/w mono-tocopheryl
phosphate and about 30.49% w/w di-tocopheryl phosphate.
[0091] It was also noted that there was about 0.21% w/w unreacted
synthetic .alpha.-tocopherol.
Example 2
[0092] Synthetic .alpha.-tocopherol and P.sub.4O.sub.10 were mixed
(mass ratio 0.170), and with heating, the exothermic reaction
temperature was reached within about 15 minutes. Heating was
continued until the reaction mixture a temperature of about
120.degree. C. was achieved and then stopped. The temperature of
the reaction mixture continued to rise for a brief period of
time.
[0093] When the exothermic reaction was complete, the reaction
mixture was allowed to cool without any external control for about
60 minutes. The reaction was then further cooled to a temperature
of about 90.degree. C. before hydrolysis with deionised water was
conducted for about 60 minutes.
[0094] The process produced about 59.26% w/w mono-tocopheryl
phosphate and about 30.91% w/w di-tocopheryl phosphate.
[0095] It was also noted that there was about 0.20% w/w unreacted
synthetic .alpha.-tocopherol.
Example 3
[0096] Natural .alpha.-tocopherol (0.07% w/w) and P.sub.4O.sub.10
were mixed (mass ratio 0.170), and with heating, the exothermic
reaction temperature was reached within about 15 minutes. Heating
was continued until the reaction mixture a temperature of about
120.degree. C. was achieved and then stopped. The temperature of
the reaction mixture continued to rise for a brief period of time.
When the exothermic reaction was complete, the reaction mixture was
allowed to cool without any external control for about 60 minutes.
The reaction was then further cooled to a temperature of about
90.degree. C. before hydrolysis with deionised water was conducted
for about 60 minutes.
[0097] The process produced about 55.79% w/w mono-tocopheryl
phosphate and about 27.68% w/w di-tocopheryl phosphate.
[0098] It was also noted that there was about 0.07% w/w unreacted
synthetic .alpha.-tocopherol.
Example 4
[0099] Propofol (1.07 g, 6.00 mmol) and P.sub.4O.sub.10 (0.430 g,
1.51 mmol) were combined in a reaction tube and stirred vigorously.
The reaction mixture was heated with a H.sub.2O bath (50-90.degree.
C.) for over 120 minutes so that the exothermic reaction was
complete and then hydrolysed with H.sub.2O (0.260 g) at 90.degree.
C. for 60 minutes.
[0100] After cooling to room temperature the reaction mixture was
dissolved in EtOH (30 mL), transferred to a 100 mL RBF and
concentrated in vacuo (60.degree. C. H.sub.2O bath). The residual
red oily solid was suspended in hot hexane (90 mL) and filtered
hot. The hexane filtrate was concentrated in vacuo (60.degree. C.
H.sub.2O bath) to .about.25 mL and then cooled on an ice bath for
about 120 minutes. The cold suspension was filtered in vacuo and
the filter cake was washed with cold hexane (3.times.15 mL) and
dried in a vacuum oven (55.degree. C.) to give a white powder.
[0101] Mass spectrometry analysis of the end product indicated the
formation of the desired monophosphate derivative of propofol.
Example 5
[0102] Propofol (0.565 g, 3.17 mmol), D-.alpha.-Tocopherol (1.35 g,
3.13 mmol) and P.sub.4O.sub.10 (0.462 g, 1.63 mmol) were combined
in a Radleys 12 Station Carousel reaction tube. The reaction
mixture was heated at 100.degree. C. for 120 minutes to allow the
respective exothermic reactions to complete. The reaction mixture
was then cooled to 90.degree. C. before hydrolysis with H.sub.2O
(0.360 g) at that temperature for 60 minutes.
[0103] After cooling to room temperature, the reaction mixture was
diluted with EtOH (30 mL), filtered and concentrated in vacuo
(60.degree. C. H.sub.2O bath) to give a brown oil substance.
[0104] Mass spectrometry analysis of the end product indicated the
formation of the monophosphate derivatives of propofol and
D-.alpha.-tocopherol, as well as the cross-coupled phosphate
diester.
Example 6
[0105] Lauryl alcohol (0.990 g, 5.31 mmol) and P.sub.4O.sub.10
(0.530 g, 1.87 mmol) were combined in a Radleys 12 Station Carousel
reaction tube and stirred vigorously. The reaction mixture was
heated at 100.degree. C. for 60 minutes and the exothermic reaction
to complete. The reaction mixture was then cooled to 90.degree. C.
before hydrolysis with H.sub.2O (0.140 g) at that temperature for
60 minutes.
[0106] After cooling to room temperature, the reaction mixture was
partitioned between Et.sub.2O (6 mL) and H.sub.2O (6 mL). The
Et.sub.2O phase was concentrated in vacuo (60.degree. C. H.sub.2O
bath) to give a yellow liquid.
[0107] Mass spectrometry analysis of the end product indicated the
formation of the desired monophosphate derivative of lauryl
alcohol.
Example 7
[0108] .beta.-Estradiol (0.490 g, 1.80 mmol) and P.sub.4O.sub.10
(0.140 g, 0.493 mmol) were combined in a Radleys 12 Station
Carousel reaction tube and suspended in Triacetin (2 mL). The
reaction mixture was heated at 100.degree. C. for 60 minutes and to
complete the exothermic reaction. The reaction mixture was then
cooled to 90.degree. C. before it was hydrolysed with H.sub.2O
(1.00 g) at that temperature for 60 minutes.
[0109] After cooling to room temperature, the reaction mixture was
washed with hexane (2.times.25 mL). The resultant suspension was
dissolved in THF (30 mL) and concentrated in vacuo (60.degree. C.
H.sub.2O bath) to give an oily beige solid. Mass spectrometry
analysis of the end product indicated the formation of the desired
monophosphate derivative.
[0110] In the claims which follow and in the preceding description
of the invention, except where the context requires otherwise due
to express language or necessary implication, the word "comprise"
or variations such as "comprises" or "comprising" is used in an
inclusive sense, i.e. to specify the presence of the stated
features but not to preclude the presence or addition of further
features in various embodiments of the invention.
* * * * *